Physician profile
Meetali Bindra
NPI 1043932973
$3,671.96
in general payments reported to CMS, 2019-2025
13 companies · $1,892 in 2025
The $1,892 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $703 · 2024: $1,076 · 2025: $1,892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,671.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,669.08 | 2023-2025 | General - Pain Management, Wavewriter Alpha Prime 16 |
| Biotronik Nro, INC. | $852.53 | 2024-2025 | Prospera |
| Electronic Waveform Lab, INC. | $440.60 | 2025 | |
| Globus Medical, INC. | $145.92 | 2025 | Vyrsa V1 |
| 4web, INC. | $138.14 | 2023 | Spine Truss System |
| Relievant Medsystems, INC. | $115.29 | 2023 | Intracept |
| United Orthopedics LLC | $71.43 | 2025 | |
| Foundation Fusion Solutions, LLC | $70.67 | 2024 | |
| Merz Pharmaceuticals, LLC | $55.74 | 2023 | Xeomin |
| Trevena, INC. | $44.60 | 2023 | Olinvyk |
| Xtant Medical INC | $34.74 | 2024 | |
| Smith+Nephew, INC. | $18.16 | 2025 | Pico 14 |
| Amgen INC. | $15.06 | 2025 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meetali Bindra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.